Horizon, Boehringer team on oncology research, 2/13:109

Create PDF

Horizon Discovery has signed a research service collaboration deal with Boehringer Ingelheim to support Boehringer’s oncology programs by using Horizon’s Discovery toolbox for research projects and profiling compounds at the hit-to-lead, lead optimization, and preclinical stages to elucidate their anticancer properties and help guide drug discovery programs.

Under terms of the collaboration, Horizon will evaluate compounds across a broad panel of X-Man isogenic models and selected 2D/3D phenotypic assays and provide an FTE and access to Horizon’s custom cell line generation services to support the programs.